![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
1. Stavudine - Lamivudine - Nevirapine
2. Stavudine, Lamivudine, Nevirapine Drug Combination
3. Triomune
1. 811471-91-7
2. 4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;2-cyclopropyl-7-methyl-2,4,9,15-tetrazatricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-10-one;1-[(2r,5s)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione
3. Lamivudine; Stavudine; Nevirapine
4. Lamivudine/nevirapine/stavudine
5. Stavudine, Lamivudine And Nevirapine
6. Lamivudine Mixture With Nevirapine And Stavudine
7. Stv & Lmv & Nvp
8. Lamivudine, Nevirapine, And Stavudine Fixed-dose Tablet
9. Nevirapine & Lamivudine & Stavudine
10. 11-cyclopropyl-4-methyl-5,11-dihydro-6h-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one & (-)-(2'r,5's)-1-[2'-hydroxymethyl-5'-(1,3-oxathiolanyl)]cytosine & Thymidine, 2',3'-didehydro-, 3'-deoxy-
11. 4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one; 11-cyclopropyl-4-methyl-5h-dipyrido[[?],[?]][1,4]diazepin-6-one; 1-[(2r,5s)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methyl-pyrimidine-2,4-dione
Molecular Weight | 719.8 g/mol |
---|---|
Molecular Formula | C33H37N9O8S |
Hydrogen Bond Donor Count | 5 |
Hydrogen Bond Acceptor Count | 12 |
Rotatable Bond Count | 5 |
Exact Mass | 719.24858035 g/mol |
Monoisotopic Mass | 719.24858035 g/mol |
Topological Polar Surface Area | 250 Ų |
Heavy Atom Count | 51 |
Formal Charge | 0 |
Complexity | 1120 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
1 of 2 | |
---|---|
Drug Name | Lamivudine; stavudine; nevirapine |
Active Ingredient | stavudine; Lamivudine; nevirapine |
Dosage Form | Tablet; Tablet, dispersible |
Route | oral |
Strength | 100mg; 6mg; 30mg; 200mg; 150mg; 12mg; 50mg; 30mg; 40mg; 60mg |
Market Status | Tentative Approval |
Company | Cipla |
2 of 2 | |
---|---|
Drug Name | Lamivudine; stavudine; nevirapine |
Active Ingredient | stavudine; Lamivudine; nevirapine |
Dosage Form | Tablet; Tablet, dispersible |
Route | oral |
Strength | 100mg; 6mg; 30mg; 200mg; 150mg; 12mg; 50mg; 30mg; 40mg; 60mg |
Market Status | Tentative Approval |
Company | Cipla |
Anti-HIV Agents
Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. (See all compounds classified as Anti-HIV Agents.)
Reverse Transcriptase Inhibitors
Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. (See all compounds classified as Reverse Transcriptase Inhibitors.)
J - Antiinfectives for systemic use
J05 - Antivirals for systemic use
J05A - Direct acting antivirals
J05AR - Antivirals for treatment of hiv infections, combinations
J05AR07 - Stavudine, lamivudine and nevirapine